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α-Synuclein aggregation and fibrillation are closely associated with the formation of Lewy bodies in neurons and are implicated in
the causative pathogenesis of Parkinson’s disease and other synucleinopathies. Currently, there is no approved therapeutic agent
directed toward preventing the protein aggregation, which has been recently shown to have a key role in the cytotoxic nature of
amyloidogenic proteins. Flavonoids, known as plant pigments, belong to a broad family of polyphenolic compounds. Over 4,000
flavonoids have been identified from various plants and foodstuﬀs derived from plants and have been demonstrated as potential
neuroprotective agents. In this study 48 flavonoids belonging to several classes with structures diﬀering in the position of double
bonds and ring substituents were tested for their ability to inhibit the fibrillation of α-synuclein in vitro. A variety of flavonoids
inhibited α-synuclein fibrillation, and most of the strong inhibitory flavonoids were also found to disaggregate preformed
fibrils.
1. Introduction
Parkinson’s disease (PD) is a chronic progressive disease,
characterized clinically by resting tremor, bradykinesia
(slowness in initiating movements), and rigidity. As only a
small number of cases are diagnosed before the age of 50,
PD is typically considered an aging disease, with a prevalence
of approximately 2% after the age of 65 [1]. The cause of
this neurodegenerative disease is still mysterious, although
considerable evidence suggests a multifactorial etiology
involving genetic susceptibility and environmental factors.
In PD, neuronal death is localized to dopaminergic
neurons in the substantia nigra region of the brain stem
and precedes appearance of symptoms. It is believed that
ca. 70% of neurons may have died by the time symptoms
become apparent [2]. Diagnosis can only be definitively
confirmed post mortem, by histopathological examination
for the pigmented neuron loss and the presence of Lewy
bodies (LBs) and Lewy neuritis (LNs) [3]. LBs are spherical
protein inclusions found in the cytoplasm of surviving nigral
neurons consisting of a dense core surrounded by a halo of
radiating fibrils of α-synuclein, the major component of LBs
[4]. A variety of other proteins have also been identified in
LBs [5, 6]. However, both the mechanism underlying the
formation of LBs and their pathogenic relevance are still
unclear [7, 8].
Substantial evidence suggests that the aggregation of α-
synuclein is a critical step in the etiology of PD [9–11]. The
following observations are among the most compelling for
the involvement of α-synuclein and its aggregation in PD:
(i) fibrils of α-synuclein are observed in LBs and LNs, the
characteristic hallmarks of the PD pathology [4, 12, 13];
(ii) three missense mutations, A53T, A30P, and E46K in α-
synuclein, lead to familial early onset Parkinson’s disease
[14–16]; A53T and A30P were known to increase the aggre-
gation propensity of α-synuclein [17, 18]; (iii) genetic studies
have shown that several cases of familial early onset PD are
caused by overexpression of α-synuclein due to duplication
or triplication of the α-synuclein gene locus (SNCA) [19, 20].
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Several possible mechanisms for the observed cyto-
toxicity of amyloidogenic assemblies have been suggested.
One mechanism suggests a direct eﬀect of amyloidogenic
assemblies on cell membrane structure and integrity,
either through the pore formation [21–26], or via the
destabilization of amyloidogenic bundles [27, 28].
Currently, no preventive therapy is available for PD.
It is believed that compounds that slow and/or prevent
aggregation and fibrillation of α-synuclein could represent
potential drug leads for PD prevention. Therefore, many
of the latest therapeutic strategies are aimed at inhibiting
fibril formation and at promoting fibril clearance. They
include the use of antibodies, synthetic peptides, molecular
chaperones, and chemical compounds. In the past few years
small organic molecules, especially certain polyphenolic
compounds, have been extensively tested for their ability to
inhibit fibril formation in vitro, particularly in relation to Aβ
deposition [29], the formation of protease-resistant forms of
the prion protein [30], the aggregation of huntingtin [31],
and the heparin-induced formation of tau filaments [32, 33].
An analysis of these reports shows that certain polyphenols
dramatically inhibit cell death in the amyloidogenic cytotox-
icity assays.
Less is known about eﬀects of polyphenols and other
small organic molecules on α-synuclein fibril formation.
Only the antituberculosis drug rifampicin and Chinese
herbal drug baicalein from Scutellaria baicalensis have been
analyzed and shown to inhibit α-synuclein fibrillation
[36–38].
Flavonoids have been known as plant pigments for over
a century and belong to a broad class of polyphenolic
compounds. Over 4,000 flavonoids have been identified from
various plants [39] and foodstuﬀs derived from plants, form-
ing substantial constituents of the human diet. The intake
of flavonoids is in the range of 50–800 mg/day, depending
on the consumption of vegetables and fruits and of specific
beverages, such as red wine, tea, and unfiltered beer [40].
Most of the flavonoids are very potent antioxidants, which
has often been associated with their health-related eﬀect.
Due to their low redox potentials (0.23 < E7 < 0.75 V) [41],
flavonoids (Fl–OH) are thermodynamically able to reduce
highly oxidizing free radicals with redox potentials in the
range 2.13–1.0 V [42], by hydrogen atom donation:
Fl–OH + R• −→ Fl–O• + RH (1)
where R• represents superoxide anion, peroxyl, alkoxyl, and
hydroxyl radicals [43–45]. The aroxyl radical (Fl–O•) may
react with a second radical, acquiring a stable quinone
structure (Figure 1(b)). Scavenging of free radicals plays a
considerable role in the antioxidant activity of flavonoid
compounds [46]. In recent years, flavonoids, being potent
free radical scavengers, have attracted a tremendous interest
as possible therapeutics against free radical-mediated dis-
eases associated with the oxidative stress [47].
Oxidative stress is an imbalanced state where excessive
quantities of reactive oxygen species (ROS), such as superox-
ide radical anion, hydrogen peroxide, and hydroxyl radical,
are present at levels higher than required for normal cell
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Figure 1: (a) Basic structure of a flavonoid, a C15-skeleton showing
the A, B, and C ring, reproduced from [34]. (b) Scavenging of ROS
(R• ) by flavonoids, reproduced from [35].
function and overwhelm endogenous antioxidant capacity
and repair [48, 49]. Oxidative stress has been linked to
cancer, aging, atherosclerosis, ischemic injury, inflammation,
and neurodegenerative diseases such as Parkinson’s and
Alzheimer’s diseases [50–53].
As recently reviewed by Pietta [34], several attempts have
been made by numerous authors to establish the relationship
between flavonoid structure and their radical-scavenging
activity [54–57]. In general, the radical-scavenging activities
of flavonoids depend on the molecular structure and the
substitution pattern of hydroxyl groups, that is, on the
availability of phenolic hydrogens and on the possibility of
stabilization of the resulting phenoxyl radicals via hydro-
gen bonding or by expanded electron delocalization [58–
60]. Besides the radical scavenging activity, the ability of
flavonoids to chelate (bind) metal ions also contributes to
their antioxidant activity in vitro. The proposed binding sites
for trace metals to flavonoids are basically consistent with
the structural requirements for eﬀective radical scavenging,
suggesting that metal chelation and antioxidant activity are
intimately linked.
Oxidative stress, transition metal accumulation, and
inflammation appear to play a role in the pathology of several
neurodegenerative diseases, including Parkinson’s disease.
Accumulated evidence has suggested that dietary flavonoids
could be potential neuroprotective agents. For example, the
consumption of flavonoid-rich blueberries or strawberries
can reverse cognitive and motor behavior deficits in rats
[62], and intake of antioxidant flavonoids is associated with
a lower incidence of dementia [63]. EGCG, a flavonoid
from green tea, has been shown to be neuroprotective in an
MPTP-induced animal model of dopaminergic degeneration
by Levites et al. [64]. The data from Griﬃoen et al.
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also demonstrated that several flavonoids counteract the
cytotoxic properties of α-synuclein aggregates directly in a
cellular context [65].
The properties of flavonoids such as their abundance
in plants and human diet, variety in composition and
structure, and antioxidative and neuroprotective biological
activities make these compounds very attractive targets while
screening small organic molecules that can interact with α-
synuclein protein and inhibit its aggregation. These natural
chemical compounds can be potentially used as therapeutic
drugs in preventing of neurodegeneration in Parkinson’s dis-
ease. Therefore, we analyzed a flavonoid library containing
48 compounds from several classes for their ability to inhibit
α-synuclein fibril formation in vitro. Many flavonoids were
shown to inhibit α-synuclein fibrillation and aggregation.
Importantly, the majority of the strong inhibitors also
disaggregate the preformed fibrils.
2. Materials and Methods
2.1. Materials. All flavonoids were obtained from IND-
OFINE chemical Co., Inc. Thioflavin T (ThT) was obtained
from Sigma-Aldrich. All other chemicals were analyti-
cal grade and obtained from Fisher chemicals or VWR
scientific.
2.2. Expression and Purification of α-Synuclein. Wild type
(WT) human recombinant α-synuclein-containing plasmid
pRK172 (obtained from R. Jakes and M. Goedert) was
transfected into Escherichia coli BL21 (DE3) cells. Protein was
induced and purified as described previously [66]. Protein
concentration was determined spectrophotometrically.
2.3. Aggregation/Fibrillation Studies and ThT Assays.
Lyophylized α-synuclein was prepared for use by dissolution
at high pH (approximately 10.5) in dilute NaOH for 5 to
10 minutes and adjusted to pH 7.4 prior to centrifugation
at 95,000 rpm with a Beckman Airfuge ultracentrifuge to
remove any aggregated material. A 5-fold dilution with
buﬀer (see text for specific conditions used) was followed
with adjustment to the desired pH. Flavonoids were dissolved
in DMSO to make a stock solution at a concentration of 5,
10, or 20 mm and to make a final solution of protein and
flavonoid in 1% DMSO unless indicated otherwise. All of the
protein final solutions consisted of PBS with 0.02% NaN3
added to avoid bacteria growth.
For plate assays, the protein solution (0.5 mg/mL or
35 μM) was mixed with flavonoids to give a final concentra-
tion of 50 μM. Three replicates of each sample were prepared
in a 96-well plate with a volume of 120 μL per well and
a 3 mm Teflon bead to provide agitation (120 rpm, 20 mm
diameter). The assays were performed in a fluorescent plate
reader (Labsystems Fluoroskan Ascent CF). Measurements
were taken at 30-minute intervals with excitation at 444 nm
and emission monitored at 485 nm.
For manual assays, the protein solution (1 mg/mL or
70 μM) was mixed with flavonoids to give a final concen-
tration of 100 μM. Protein samples were stirred at 37◦C
with a mini-Teflon stir bar. Aliquots of 5 or 10 μL were
removed from the incubated solution and added to 1 mL
of 10 μM ThT solutions in 20 mm phosphate buﬀer (pH
7.4) as a function of time to monitor the fibrillation
kinetics. ThT fluorescence was recorded at 482 nm with
excitation at 450 nm and slits of 5 nm for both excitation and
emission using a FluoroMax-3 spectrofluorometer (Jobin
Yvon Horiba).
2.4. Electron Microscopy Measurements. Transmission elec-
tron microscopy (TEM) was used to estimate the size
and structural morphology of α-synuclein. Aliquots of 5 μL
sample were deposited on Formvar-coated 300 mesh copper
grids (Ted Pella) and incubated for 5 to 10 minutes. Salts
were washed out with distilled water, and samples were
dried, negatively stained with 1% (w/v) uranyl acetate,
and visualized on a JEOL JEM-100B transmission electron
microscopy operated at 80 kV. Typical magnifications ranged
from ×75,000 to 300,000. The grids were thoroughly exam-
ined to obtain an overall evaluation of the samples. Images
were produced with Gattan Digital Micrograph software.
2.5. Electrophoresis. Sodium Dodecyl Sulfate Polyacrylamide
Gel Electrophoresis (SDS-PAGE) was carried out on an
Amersham Phast System Separation and Control Unit with
PhastGel Gradient 8-25 polyacrylamide gels. SDS buﬀer
(0.20 M tricine, 0.20 M Tris, 0.55% SDS, pH 8.1) strips
(Amersham) were used. Gel electrophoresis samples were
prepared by the addition of 3 parts of protein solution to 1
part SDS buﬀer (0.25 M Tris, 8% SDS, 60% glycerol, 0.08%
bromophenol blue, pH 6.8) and boiled for 3–5 minutes.
The 10–225 kDa protein markers were purchased from USB
Corporation (Cleveland, Ohio, USA).
Isoelectric Focusing (IEF) Polyacrylamide Gel- IEF-
Polyacrylamide Gel (4–6.5) was carried out on an Amer-
sham Phast System Separation and Control Unit with
IEF polyacrylamide gels. PI standards contain proteins as
follows: Human carbonic anhydrase B: 6.55; Bovine carbonic
anhydrase B: 5.85; β-Lactoglobulin A: 5.20; Soybean trypsin
inhibitor: 4.55; Glucose oxidase mannitol: 4.15; Methyl red
(dye): 3.75; Amyloglucosidase: 3.50; Pepsinogen: 2.80.
2.6. Chromatography: Size Exclusion (SEC) HPLC Measure-
ments. An aliquot of each sample was removed from the
α-synuclein incubation at various times, and the insoluble
material was removed by centrifugation for 20 minutes at
14,000 rpm. Sample volumes of 40 μL of supernatant were
eluted from a TSK-GEL G4000SWXL size exclusion column
(7.8 mm inner diameter × 30 cm) in 20 mm phosphate
buﬀer, pH 7.0, and 100 mm Na2SO4 using a Waters 2695
separations module with a Waters 996 photodiode array
detector. The HPLC system was controlled, and data were
collected and analyzed by Millennium software. The col-
umn was eluted at a flow rate of 0.5 mL/min, and the
absorbance of the mobile phase was monitored over the
wavelength range from 220 to 450 nm with a bandwidth
of 1.2 nm. The retention times were calibrated with the
following protein molecular mass standards: ribonuclease
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A (13.6 kDa), chymotrypsinogen A (25 kDa), ovalbumin
(43 kDa), albumin (bovine serum) (67 kDa), and aldolase
(158 kDa). The void volume was determined with blue
dextran 2000 (∼2000 kDa).
2.7. Electrospray Ionization Mass Spectrometry (ESI-MS).
Samples for mass spectrometry analysis were desalted with
C8 reverse phase column and eluted out with 80% ace-
tonitrile adjusted with TFA to a final pH at 2.0. Injection
was carried out via a Harvard Apparatus (Holliston, MA)
syringe pump at a flow rate of 20 μL/min. Mass spectra
were obtained using Micromass ZMD electrospray mass
spectrometer operating in positive ionization mode. The
source temperature was set to 80◦C, and the capillary voltage
was 3.25 kV. Protein molecular weight was determined from
m/z by Masslynx software.
3. Results and Discussion
3.1. Eﬀects of Various Flavonoids on the Fibrillation
of α-Synuclein
3.1.1. Fibrillation Kinetics ofWT α-Synuclein in the Presence of
Various Flavonoids. In this study, 48 flavonoids belonging to
several classes with structures diﬀering in ring substituents
and in the nature/extent of alkylation have been tested
for their ability to inhibit the fibrillation of α-synuclein in
vitro. These flavonoids include 18 flavones, 12 flavonols, 4
flavanones, 6 isoflavones, 2 dihydroflavonols, 3 catechins,
and 3 anthraquinones. Flavonols and flavones accounted for
the majority of the study because of their wide distribution
in foods. Table S1 (see Table S1 in Supplementary Materials
available online at doi:10.1061/2010/650794.) lists the name,
synonym, and structure of the flavonoid from each class. The
basic flavonoid structure is the flavan core, which consists
of a 15 carbon skeleton (C6-C3-C6), arranged in three rings
labeled as A, B, and C in Figure 1(a) [34]. The various classes
of flavonoids diﬀer in the level of oxidation and pattern of
substitution of the C ring, including flavonols (quercetin and
kaempherol), flavanols (the catechins), flavones (apigenin),
and isoflavones (genistein). Individual compounds within a
class diﬀer in the pattern of substitution of the A and B rings.
Figure 2 represents kinetic profiles of α-synuclein fibril
formation in the absence (circles) or presence of diﬀerent
flavanoids, as monitored by changes in the ThT fluorescence.
Diﬀerent flavonoids aﬀected the α-synuclein fibrillation to
a diﬀerent extend. Some flavonoids, such as 22-357 and
22-344 (Figure 2, inverted triangles), slightly inhibited the
fibrillation of α-synuclein, increasing the lag time 2- to 3-fold
in comparison with that of the control, and were classified as
weak (+) inhibitors. Other flavonoids, such as quercetin and
G-500 (Figure 2, squares), significantly inhibited α-synuclein
fibrillation, with the lag time 4- to 5-fold longer than that of
the control, and were classified as good (++) inhibitors.
In the presence of 6-HP (Figure 2, diamonds), α-
synuclein fibrillation was completely inhibited, as indicated
by the negligible changes in the ThT fluorescence over the
time course. More importantly, no detectable α-synuclein
fibrillation was observed for about 3 days or longer. The
inhibitory eﬀect of 6-HP on α-synuclein fibrillation was as
good as that from baicalein (Figure 2), which was reported
earlier by Zhu et al. [36]. Besides 6-HP, several other
new flavonoids from diﬀerent classes including eriodictoyl,
22-324, myricetin, EGCG, T-415, 22-340/tricetin, and 22-
341, also exhibited strong inhibitory eﬀects on α-synuclein
fibrillation. Flavonoids that completely inhibited the fibril
formation of α-synuclein under the current experimental
conditions were classified as strong inhibitors (designated as
+++). The inhibitory activities of each flavonoid analyzed
in this study are listed in Table S1 (see Supplementary
Table S1).
In general, the intensity of ThT fluorescence was pro-
portional to the amount of fibril forms. For instance, in
the presence of the inhibitory flavonoids, the fluorescence
intensity at the end of reaction was in the decreasing
order: control (no flavanoid) > 22-257 > quercetin > 6-HP.
EM analysis revealed that the detectable amount of fibrils
formed at the end of the reaction was decreasing in the
same order. In the plate assays, however, most of the tested
compounds gave artificially low ThT signal. For example, in
the presence of some flavonoids, such as wogonin, diosmetin,
and tamarixetin (Figure 3), the ThT fluorescence intensity
was much lower than the control, whereas the kinetics of α-
synuclein fibrillation still exhibited a typical sigmoidal shape,
with the lag time similar to the control. Since the amount
of fibrils formed at the end of reaction was found to be
similar to that of the control, as indicated by the EM imaging,
the lower ThT fluorescence intensity for samples containing
these flavonoids suggested that flavanoids either quenched
the ThT fluorescence or competed with ThT at the binding
site on the protein fibrils. Therefore, no matter how much the
flavonoids diminished the ThT fluorescence, as long as they
did not prolong the lag time of α-synuclein fibrillation, such
as 19-612, chrysoeriol, wogonin, and tamarixetin, and they
were all classified as noninhibitors (designated as −).
The quenching/competition was verified by titrations of
fibril-ThT complex with various flavonoids. The increasing
concentrations of flavonoids from diﬀerent classes were
added to a certain amount of existing fibrils in the presence
of 10 μM ThT solution. The intensity of ThT fluorescence in
the presence of fibrils decreased as a function of flavanoid
added and approached a certain saturation level when the
concentration of the flavonoid was around 50 μM (Figure 4).
The decrement degree was dependent on the number and
the arrangement of hydroxyl groups for flavonoids from
the same class (e.g., flavanones: homoeriodictyol, hesperetin,
and eriodicyol) and on the level of saturation of Ring C
for flavonoids from diﬀerent classes but with comparable
structures (e.g., flavanones with 2, 3 double bond in Ring C
compared with the corresponding flavones).
Figure S2 (see Supplementary Figure S2) shows instant
changes in the ThT fluorescence intensity measured in the
presence of α-synuclein fibrils and 50 μM flavonoids. The
addition of several flavonoids, such as 6-HP, myricetin, G-
500, and emodin, resulted in almost 20-fold decrease in the
ThT fluorescence intensity in comparison with the control
signal.
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Figure 3: The kinetics of α-synuclein fibrillation in the presence
of noninhibitory flavonoids by ThT plate reader assays. Each curve
was obtained by fitting the data with Sigma Plot, using the equation
from [61].
To avoid interference of flavonoids on ThT fluorescence,
manual ThT assays were employed. The final ratio of
flavonoid to ThT in the manual assay was lower (about
1 : 10) compared with that in the plate assay; therefore the
quenching by flavonoids was almost completely eliminated.
Figure 5 compares the results of the plate assay and the man-
ual assay for the fibrillation of α-synuclein in the presence
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Figure 4: Titration of existing fibril-ThT complex by flavonoids.
Structures of the flavonoids are listed on the right side. ThT
concentration: 10 μM. Cuvette volume: 1 mL. With excitation at
450 nm, fluorescence emission at 482 nm was measured upon the
addition of flavonoid.
of one of the non-inhibitory flavonoids, tamarixetin. In the
plate assay, ThT fluorescence intensity in the presence of
50 μM tamarixetin was much lower (∼10-fold) than that
in the absence of the flavonoid, whereas in the manual
assay, the addition of 50 μM tamarixetin did not aﬀect
ThT fluorescence intensity (Figure 5). Similar results were
obtained when manual ThT assays were performed with
other non-inhibitory flavonoids (data not shown).
All potential inhibitory flavonoids identified in high-
throughput plate-reader assays were tested in subsequent
manual assays. In addition, the presence of fibrils was
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Figure 5: The eﬀect of tamarixetin on the ThT fluorescence of α-
synuclein fibrillation by two ThT assays: the plate reader assay (a)
and the manual assay (b).
evaluated by EM and quantitatively estimated from SDS
PAGE of supernatant fractions (described below).
3.2. Analysis of α-Synuclein Species Formed in the Presence
of Flavonoids. During storage or incubation, monomeric α-
synuclein tends to self-associate into complexes of various
degrees including dimers, trimers, oligomers of various
size and shapes, protofibrils, and fibrils. Based on EM,
DLS, SEC, and SDS-PAGE, the typical distribution of α-
synuclein species after 3 days of incubation was 75%–
85% of fibrils, 5%–10% of protofibrils, and 5%–20% of
oligomeric species and amorphous aggregates. The non-
inhibitory flavonoids did not aﬀect the distribution and
(a)
0.2 μm
(b)
0.2 μm
(c)
Figure 6: TEM images of α-synuclein samples after 3 days of
incubation in the absence (a) and presence of weak/good (b) and
strong (c) inhibitors of α-synuclein fibrillation.
morphology of fibrils (Figure 6(a)). Typical fibrils were
10 ± 1 nm in width and up to about 2 μm in length.
Flavonoids classified as weak or good inhibitors decreased
fibril amounts. Remained fibrils were shorter in length but
similar in width (Figure 6(b)). When α-synuclein was incu-
bated with strong inhibitory flavonoids only oligomers and a
few protofibrils instead of fibrils were detected (Figure 6(c)).
Flavonoid-induced protofibles were 5–10 times shorter in
length and twice smaller in width compared with the typical
α-synuclein fibrils. Flavonoid-induced oligomers appeared as
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round- or oval-shaped species with a 10–20 nm diameter.
Their morphology was similar to the oligomeric species
observed in the absence of flavonoids; however, the detailed
structure and assembly could be diﬀerent. Unfortunately, this
is beyond the detection limits of AFM and EM. Inhibitory
flavonoids greatly aﬀected the distribution of aggregated α-
synuclein species apparently by stabilizing monomeric and
oligomeric species.
The distribution and stability of soluble species of α-
synuclein were analyzed by SEC and SDS-PAGE. In addition,
SDS PAGE was employed to quantitatively estimate the
amount of protein in the supernatant and pellet fractions
because Lowry and other spectrophotometric methods
could not be used due to flavonoid interference with the
absorbance. Figure 7(a) shows SDS-PAGE of supernatant
fractions of α-synuclein samples incubated in the absence
or presence of the strong inhibitory flavonoids. In the
control lane, a weak band of monomeric α-synuclein was
observed indicating that most of the protein was insoluble.
No dimers or oligomers were detected. In the presence of
non-inhibitory flavonoids such as H-114 and 22-323, there
was also a relatively weak band of monomeric α-synuclein
in the gel (Figure 7(b)), similar to that of the control further
confirming that these flavonoids did not aﬀect α-synuclein
fibrillation. On the other hand in the presence of strong
inhibitory flavonoids such as 6-HP and 22-324, essentially all
of the protein was present in the supernatant. The monomer
band was much intense than that of the control. Importantly,
higher molecular weight species were also detected on SDS
gel. They correspond to dimers (35 kDa band), trimers
(50 kDa band), and oligomers (a band on the top of the gel).
The oligomeric species and dimer/trimers were resistant to
treatment with SDS at 100◦C for 20 minutes. They were also
extremely stable in 8 M urea and 6 M GdmHCl (data not
shown). The stability of these oligomers and dimers indicates
that they are diﬀerent from the similar species formed in the
absence of flavonoids, which are unstable in the mentioned
conditions. The extreme stability can be due to very strong
noncovalent interactions and/or covalent binding.
The soluble forms of α-synuclein stabilized by the
flavonoids were further analyzed by size exclusion HPLC.
The elution profile of α-synuclein control sample showed
only one peak at 11.5 mL corresponding to a trace amount of
monomers (Figure 8, black curves). These results were rather
unexpected as EM, AFM, and DLS analyses revealed that
oligomers constituted the majority of the supernatant frac-
tions (data not shown). This contradiction can be explained
by the instability of oligomers under HPLC condition and by
their fast dissociation upon dilution during chromatographic
process. On the contrary, SEC analysis revealed that soluble
fractions of α-synuclein incubated with flavonoids contained
significant amounts of oligomers. Oligomeric fractions of α-
synuclein were obtained by running FPLC, which required
much more protein for analysis and was used only for some
flavonoid-protein samples (data not shown). The elution
profiles of α-synuclein incubated in the presence of non-
inhibitory flavonoids such as wogonin and kaempferol were
similar to the control profile (Figure 8(b)). Peaks eluted
after the monomer peak (13.5 and 14 mL) corresponded
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Figure 7: (a) SDS-PAGE from the supernatants of the incubated
samples of α-synuclein in the absence and presence of the strong
inhibitory flavonoids. (b) Comparison of the eﬀect of strong
inhibitory flavonoids (6-HP, 22-324) with noninhibitory flavonoids
(H-114, 22-323) on formation of stabilized soluble species.
to polymerized forms of flavonoids that occurred during
incubation [67]. The flavonoid nature of the peaks was
experimentally confirmed by the same elution times and
absorbance spectra of incubated flavonoid alone and by the
absence of protein band on SDS gel for the concentrated
fraction sample from SEC-HPLC (data not shown).
The elution profiles of α-synuclein incubated in the pres-
ence of inhibitory flavonoids had six major peaks. Besides
the monomer and flavonoid peaks, peaks corresponding to
dimer (11 mL), trimer (10.3 mL), and small (7.8 mL) and
large oligomer (6.2 mL) were detected (Figure 8). Because
of the flavonoid interference with the protein spectra, the
protein nature of the peaks and the amount of protein
eluted was analyzed by SDS-PAGE. The increased intensity
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of the monomer peak was mostly attributed to the elevated
amount of monomers and partially to the absorbance
of flavonoid tightly bound to the monomer. Absorbance
intensity of dimer and oligomer peaks also partially cor-
responded to the flavonoid absorbance and indicated the
stability of flavonoid-protein complexes. The observation
of oligomeric species on HPLC confirms that flavonoid-
induced oligomers are more stable and thus diﬀerent from α-
synuclein oligomers obtained without flavonoids that easily
dissociate and are not detected by HPLC.
Interestingly, Figure 8 also shows that the distribution
of oligomeric forms and monomers varied depending on
the nature of flavonoid. For example, eriodyctiol mostly
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Figure 9: Secondary structure analyses of α-synuclein in the
presence of baicalein by ATR-FTIR (red lines). The spectra of
α-synuclein alone before and after incubation was presented for
comparison (black lines).
stabilized dimers and monomers, G-500 mostly monomers,
and baicalein mostly oligomers and monomers.
All inhibitory flavonoids aﬀected α-synuclein aggrega-
tion and lead to the inhibition of fibril formation, accumu-
lation of oligomeric species, and stabilization of monomers
and oligomers. Therefore, at the next stage, we analyzed
the conformational properties of flavonoid-stabilized α-
synuclein species. To this end, attenuated total reflectance
FTIR was applied to detect the secondary structure of
flavonoid-stabilized soluble species of α-synuclein. The FTIR
spectrum of fresh α-synuclein with baicalein exhibits a
typical unfolded structure, similar to fresh α-synuclein alone,
with the peak centered at 1652 cm−1 (Figure 9, solid lines).
After 3 days of incubation, the spectrum of the protein alone
changed into a structure with significant β-sheet, with the
peak at 1630 cm−1, indicative of fibril formation (Figure 9,
black lines), whereas the spectrum of the protein with the
compound did not exhibit significant structural changes
(Figure 10, red lines), reflecting that baicalein inhibits α-
synuclein fibrillation by stabilizing the natively unfolded
conformation of the protein.
3.3. Analysis of Flavonoid Inhibitory Eﬀects on Various Stages of
Fibrillogenesis. The inhibition of α-synuclein fibrillogenesis
by flavonoids may involve two diﬀerent events, the inhibition
of nucleus formation occurring during lag time or the
inhibition of fibril elongation corresponding to the linear
increase in the ThT fluorescence intensity. To resolve it,
one of the strong inhibitory flavonoids, 6-HP, was added at
various times during incubation of α-synuclein. As shown
on Figure 10(a), 6-HP stopped the progress of fibrillation
regardless of the time it was added, namely, at 0 hour
(sample L0), 12 hours (end of nucleation, sample L1), 21
hours (middle of elongation, sample L2), and 33 hours (end
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Figure 10: The eﬀect of baicalein on α-synuclein fibrillation
at diﬀerent stages by monitoring the kinetics of α-synuclein
fibrillation (a) and the SDS-PAGE of the supernatants at the end
of reaction (b) for the sample with baicalein added at various times,
that is, 0 hour (sample L0), 12 hours (end of nucleation, sample L1),
21 hours (middle of elongation, sample L2), and 33 hours (end of
elongation, sample L3).
of elongation, sample L3). Addition of 6-HP at any time
during nucleation resulted in the complete inhibition of fibril
formation. This indicated that 6-HP could act on the late
steps of nucleation such as formation of oligomers. When 6-
HP was added during linear growth of fibrils or at the end of
fibrillation, the decrease in ThT intensity and disaggregation
of formed fibrils were observed. The initial drop was mostly
due to the quenching of ThT fluorescence by the flavonoid,
and the subsequent decrease in ThT signal was due to disag-
gregation of the existing fibrils. This was confirmed by EM
and SDS-PAGE. The rates of disaggregation were similar and
did not depend on time of flavonoid addition. It was consis-
tent with explanation that the fibrillar species were similar in
structure and mechanism of disaggregation was the same.
SDS-PAGE of α-synuclein supernatant fractions with 6-
HP added at various times of incubation was run to verify
the results of ThT assays (Figure 10(b)). SDS-PAGE analy-
sis demonstrated the considerable build-up of monomers,
dimers, trimers, and higher MW oligomers as long as the
addition of 6-HP was prior to nucleation (samples L0, L1).
This indicated that the most eﬃcient inhibition took place
during, or prior to, nucleation. When 6-HP was added after
the nucleation in the middle of or at the end of fibril
elongation (L2 and L3), less amount of monomers and
oligomers was detectable.
Similar results were observed for α-synuclein with other
strong inhibitory flavonoids such as baicalein, EGCG, and
T-415. It can be concluded that the inhibitory flavonoids
stopped the progress of fibrillation at any stage. Impor-
tantly, the addition of flavonoids to the preformed fibrils
resulted in almost complete fibril disaggregation. However,
the most eﬃcient inhibition of α-synuclein fibrillation
by the flavonoids took place on or prior to nucleation
through formation of the flavonoids-stabilized monomeric
and oligomeric forms of the protein.
3.4. Structural Features of α-Synuclein Fibrillation Inhibitors.
Our results showed that a variety of flavonoids can inhibit
the fibril formation of α-synuclein. Some flavonoids can
also disaggregate existing fibrils. Among the 48 flavonoids
tested, several compounds exhibited stronger inhibitory
eﬀects than others despite the overall structural similarity of
the flavanoid family. The aim of this study was to eventually
elucidate the relationship between the molecular structure of
a series of structurally related flavonoids and their ability to
inhibit α-synuclein fibrillation.
The molecular structural requirements that appear nec-
essary to provide a flavonoid the ability to inhibit α-synuclein
fibrillation were determined to be a vicinal dihydroxyphenyl
moiety. In another words, flavonoids without any vicinal
dihydroxyphenyl moieties have no inhibitory eﬀect on α-
synuclein fibrillation.
The substitution pattern, that is, the ring to locate in
and the position on the ring, of the dihydroxyl groups
could also aﬀect the inhibitory activity but not necessarily.
For example, comparisons were made among the following
5 flavones (Figure 11(a)). The 2 flavones, D-258 with the
3′,4′-dihyhroxy substitution pattern on ring B, and D-406
with the 2′,3′-dihyhroxyl group in ring B, have a similarly
good inhibitory eﬀect on α-synuclein fibrillation. Rather
than the o-dihydroxy structure in the B ring, the other 2
flavones, D-112 and 22-357, have hydroxyl substituents in
a catechol structure on the A ring at diﬀerent positions.
The 2 compounds also have a similar inhibitory eﬀect on α-
synuclein fibrillation, but weaker than the eﬀect from D-258
and D-406. In contrast to the above 4 flavones, D-407 does
not have a vicinal dihydroxyphenyl moiety, nor does it have
any inhibitory eﬀect on α-synuclein fibrillation (see activity
in Supplementary Table S1).
Moreover, the diﬀerence in the number of vicinal dihy-
droxyl substituents and the number of individual hydroxyl
groups also brings some diﬀerence in the inhibitory activities
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Figure 11: Structural comparisons among the 5 flavones with two hydroxyl groups (a). Structural comparisons among the 4 flavonols with
diﬀerent numbers of individual hydroxyl groups or dihydroxyl groups (b).
of flavonoids. Generally, the larger the number, the stronger
it is. For instance, the 4 flavonols, T-601, 22-344, quercetin,
and G-500, all of them have the 3′,4′- dihyhroxy substi-
tution pattern on ring B, (Figure 11(b)) conferring them
the inhibitory activity. However, T-601 does not have any
individual hydroxyl group in the A ring, 22-344 has one
single hydroxyl group in ring A, quercetin has 2 individual
hydroxyl groups in ring A, and G-500 has 3 hydroxyl groups
with 2 of them adjacent. Not surprisingly, the inhibitory
activity is in the increasing order of T-601 < 22-344 <
quercetin < G-500 (data not shown).
Flavonoids with three vicinal hydroxyl groups exhibited
the enhanced inhibitory eﬀects on α-synuclein fibrillation
(structures in Figure 12). For example, 6-HP exhibited
stronger inhibitory activity than 22-357 (Figure 2); myricetin
was stronger than quercetin, and tricetin was stronger than
luteolin (data not shown). Interestingly, all the flavonoids
(except 021037) with three vicinal hydroxyl groups from
our screening were found to be strong inhibitors, that is,
completely inhibited the fibril formation within 3 days of
incubation (Figure 13(a)). The essentially weaker inhibitory
eﬀects of 021037 could result from the lack of 2,3-double
bond in this flavonoid. On the other hand, only three
flavonoids without three vicinal hydroxyl groups from this
screening were found to exhibit strong inhibitory eﬀect
on α-synuclein fibrillation. They were as follows: T-415 an
isoflavonoid, eriodictyol a flavanone, and 22-324 a flavone
(Figure 13(b)).
Inversely, the flavonoids with structures exactly the same
or very similar (the number and position of ring substitu-
tions) to those of strong inhibitors, but with hydroxyl groups
replaced by methoxyl groups, did not have any inhibitory
eﬀects on α-synuclein fibrillation, as exemplified by the
following pairs of flavonoids H-114 versus 6-HP and 22-
324 versus 22-323 (Figure 14). The details of the molecular
mechanisms underlying the flavanoid-induced inhibition
of α-synuclein fibrillation were analyzed recently [68]. It
was shown that the noncovalent binding of the inhibitory
flavonoids to α-synuclein and the covalent modification
by the flavonoid quinone led to the restriction of the
conformational changes in this natively unfolded protein and
to the stabilization of soluble flavonoid-modified species of
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α-synuclein (monomers and oligomers). All of these factors
rather than a single one contribute to the inhibition of α-
synuclein fibrillation induced by the flavonoid. The struc-
tural requirements for flavonoid to be a good inhibitor of α-
synuclein fibrillation were vicinal dihydroxyphenyl moieties,
irrespectively of their positions in the rings. Flavonoids with
three vicinal hydroxyl groups exhibited enhanced inhibitory
eﬀects on α-synuclein fibrillation. The antioxidant activities
of flavonoids were generally correlated with their in vitro
inhibitory eﬀects on α-synuclein fibrillation [68].
3.5. Implications for the Treatment of PD. PD has a multifac-
torial etiology depending on genetic susceptibility and envi-
ronmental factors. From epidemiological and environmental
studies, oxidative stress, transition metal accumulation, and
inflammation appear to play a role in the pathology of PD.
However, the detailed molecular mechanisms of triggering
the oxidative stress as well as targets of transition metal action
are not known. The cause of inflammation is also unknown.
From genetic etiological studies, α-synuclein misfolding and
aggregation as well as impairment in the cellular folding
machinery appear to be important in the early onset of PD.
However, functions of α-synuclein, a cause of protein aggre-
gation, and its role in the triggering of neurodegeneration
are still unknown. Recently, it has been proposed that α-
synuclein may interact with mitochondrial membranes and
aﬀects their structures. This interesting idea may consolidate
genetic and environmental studies of PD etiology. α-
Synuclein could be a key factor, upon which oxidative stress
or transition metals act resulting in protein aggregation
or oligomerization that in turn aﬀect mitochondrial
membranes leading to mitochondrial dysfunctions including
elevated ROS production, leakage of cellular membrane
compartments, cell death, and inflammation. Therefore, the
prevention of protein aggregation and oligomerization is
an attractive strategy in combating the neurodegeneration
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because it acts on the very beginning of the proposed
cellular pathway leading to cell death. In our study, we
analyzed 48 flavonoids for their eﬃciency to inhibit α-
synuclein aggregation in vitro by stabilizing nonpathogenic
protein conformations. Majority of the flavonoids inhibit α-
synuclein polymerization either delaying or completely abol-
ishing fibril formation. The thermodynamic distributions of
α-synuclein species are tremendously altered in the presence
of strong flavonoid inhibitors. Flavonoids such as 6-HP,
eriodictyol, G-500, and baicalein tightly bind to the protein
and greatly stabilize its natively unfolded conformation. The
major species existing in the thermodynamic equilibrium
in the presence of flavonoids are oligomers and monomers.
Flavonoid compounds show diﬀerent ratios in distribution
of monomers and oligomers indicating that they stabilize
mostly either monomeric or oligomeric conformations.
Most importantly, strong inhibitors disaggregate preformed
fibrils.
Substantial evidence reveals that flavonoids act in vivo as
health-beneficial and neuroprotective agents. For example,
baicalein, a typical flavonoid compound, is the main com-
ponent of a traditional Chinese herbal medicine Scutellaria
baicalensis. Recent studies have shown that baicalein protects
rat cortical neurons from amyloid β-induced toxicity by
its inhibition of lipoxygenase [69]. Natural medicines
containing these compounds have been reported to have
beneficial eﬀects in treating memory loss and dementia
[70, 71]. Another flavonoid, (−)-epigallocatechin-3-gallate
(EGCG), has been shown neuroprotective in an MPTP-
induced animal model of dopaminergic degeneration
[64]. Their data from the yeast model also demonstrated
that flavonoids counteract the cytotoxic properties of
α-synuclein toxicity directly in a cellular context [65].
Epidemiological studies suggest an inverse relation between
flavonoid intake and incidence of chronic diseases, such
as coronary heart disease [72–74], as well as dementia and
other neurodegenerative diseases [63, 70].
However, little is currently known about the mechanism
of flavonoid action in vivo. There are two models that explain
the flavonoid health beneficial eﬀects. First model suggests
that the antioxidant properties of flavonoids are important
in combating oxidative stress by scavenging radicals and by
metal chelation. However, even with very high flavonoid
intakes, plasma and intracellular flavonoid concentrations
in humans are likely to be 100–1,000 times lower than
concentrations of other antioxidants, such as ascorbate or
glutathione. Furthermore, most circulating flavonoids are
actually flavonoid metabolites, some of which have lower
antioxidant activity than the parent flavonoid. For these
reasons, the relative contribution of dietary flavonoids to
plasma and tissue antioxidant function is most likely to be
relatively minor [75, 76].
The second model postulates that many of the biological
eﬀects of flavonoids can be related to their ability to
modulate cell-signaling pathways rather than to act as
antioxidants. For instance, several signaling mechanisms
were suggested to explain polyphenol-induced protection
against amyloid cytotoxicity [77] and the neuroprotective
eﬀects of flavonoids [78]. The validity of the hypothesis
is supported by the facts that intracellular concentrations
of flavonoids required to aﬀect cell signaling pathways are
considerably lower than those required to impact cellular
antioxidant capacity, and flavonoid metabolites may still
retain their ability to interact with cell signaling proteins,
even if their antioxidant activity is diminished.
Our results have demonstrated that flavonoids signif-
icantly aﬀect α-synuclein propensity to aggregate in vitro
through binding and stabilizing the certain protein confor-
mations. This direct act of flavonoids on protein aggregation
is a highly possible mechanism of flavonoid action in vivo.
The apparent Kd of flavonoid-α-synuclein complexes is in
range of 200–800 nm, which is suﬃcient for binding of
flavonoids in vivo [68]. Furthermore, there is a certain
correlation between antioxidant activities of flavonoids and
their in vitro inhibitory eﬀects on α-synuclein fibrillation;
thus it is possible that the antioxidant potential of flavonoids
may relate not only to the scavenging of radicals and
metals but also to binding to amyloidogenic proteins such
as α-synuclein, locking the certain protein structures, and
abolishing protein aggregation.
It has been suggested that the precursors of fibrils, the
transient oligomers, and protofibrils on the aggregation
pathway in neurodegenerative diseases might be more toxic
than fibrils [21, 22]. Hence, it can be argued that the
flavonoid-induced oligomers from our study could be more
cytotoxic than fibrils. Several studies have been done to test
the cytotoxicity of one of the flavonoid-synuclein complexes,
the baicalein-stabilized oligomers, and have demonstrated
their benign eﬀects on membrane permeability [38], cell
culture toxicity [79], and neuron degeneration in worms and
mice. Masuda et al. have reported that, unlike α-synuclein
fibrils and protofibrils, flavonoid-induced soluble oligomeric
species did not reduce the viability of human dopaminergic
neuroblastoma SH-SY5Y cells [79]. These findings suggest
that the soluble oligomers formed in the presence of
inhibitory flavonoids may not be toxic to human neurons
and that these flavonoids may therefore have therapeutic
potential for PD and other amyloidoses.
Flavonoids are among the most secure and reliable sub-
stances available now for preventing various diseases includ-
ing maladies related to the oxidative-stress and neurodegen-
eration. In this study, we have demonstrated that flavonoids
can directly act on aggregation of α-synuclein, being able to
inhibit fibrillation and disaggregate the preformed fibrils into
monomers and nonpathogenic oligomers. This implies that
flavonoids may have been already combating PD, and that
diets rich in flavonoids may be eﬀective in preventing and
curing the disorder.
Supporting Information Available
Experimental details of the inhibitory activities of each
flavonoid analyzed in this study are available; the figures
illustrate instant changes in the intensity of ThT fluorescence
upon adding 50 μM flavonoids directly to the existing α-
synuclein fibril solution. This material is available free of
charge via the Internet at http://pubs.acs.org.
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